Arnab Ghosh
1.5K posts
@Ghoshomy
Physician Scientist in drug development | Alum of Adult BMT/ Cell Therapy/ Med Oncology Fellowship Memorial Sloan Kettering Cancer Center | IM Residency MSSM
Check it out! Our Department of Pediatrics is currently being featured by @humansofny: facebook.com/humansofnewyor…
A new drug is showing promise in lung and pancreatic cancers (two of the most aggressive forms of cancer) by targeting one of the most common cancer-driving mutations. Researchers at Memorial Sloan Kettering Cancer Center (MSK), including gastrointestinal medical oncologist @CentralParkWMD who led the global phase 1 clinical trial, shared results published in the @NEJM. The trial tested setidegrasib, a drug that tags and destroys the cancer-causing protein produced by the KRAS G12D mutation. This new method for targeting a long-known mutation is called a KRAS degrader. KRAS mutations are present in about 1 in 5 cancers. The G12D subtype drives about 40% of pancreatic cancers and 5% of non-small cell lung cancers. “This drug’s potential is exciting,” says Dr. Park, “because the trial results suggest that setidegrasib can not only extend life for some patients with these aggressive cancers, it also has a very good safety profile, meaning the drug was well-tolerated with side effects that can be managed quite easily." Learn more about this research: bit.ly/4lSeoJa
I came to Gaines County, Texas, today to comfort the Hildebrand family after the loss of their 8-year-old daughter Daisy. I got to know the family of 6-year-old Kayley Fehr after she passed away in February. I also developed bonds with and deep affection for other members of this community during that difficult time. My intention was to come down here quietly to console the families and to be with the community in their moment of grief. I am also here to support Texas health officials and to learn how our HHS agencies can better partner with them to control the measles outbreak, which as of today, there are 642 confirmed cases of measles across 22 states, 499 of those in Texas. In early March, I deployed a CDC team to bolster local and state capacity for response across multiple Texas regions, supply pharmacies and Texas run clinics with needed MMR vaccines and other medicines and medical supplies, work with local schools and healthcare facilities to support contact investigations, and to reach out to communities, including faith leaders, to answer any questions or respond to locations seeking healthcare. Since that time, the growth rates for new cases and hospitalizations have flattened. The most effective way to prevent the spread of measles is the MMR vaccine. I’ve spoken to Governor Abbott, and I’ve offered HHS’ continued support. At his request, we have redeployed CDC teams to Texas. We will continue to follow Texas’ lead and to offer similar resources to other affected jurisdictions.
